argenx, a global immunology company, is hosting a webinar on June 23, 2026, focused on advancing research and development of FcRn blockers for autoimmune myositis. The event features argenx's management and scientific leaders alongside key external experts from Harvard, Northwestern, and the University of Pittsburgh. This webinar highlights argenx's commitment to developing novel antibody-based medicines for severe autoimmune diseases, including their first approved neonatal Fc receptor blocker. A live webcast and replay will be available on argenx's investor website, supporting transparency and engagement with investors and the medical community.
The European Commission has approved Cenrifki (tolebrutinib) by Sanofi for treating secondary progressive multiple sclerosis (SPMS) without relapses, based on positive phase 3 trial results showing it delays disability progression. This is the first ...
Signify announced a new strategy at its 2026 Capital Markets Day to become a more focused and better-performing company by 2029. The plan includes prioritizing growth in connected lighting and consumer segments while optimizing less profitable areas....
The European Commission has approved Sanofi's Cenrifki (tolebrutinib) as the first medicine targeting disability progression in secondary progressive multiple sclerosis (SPMS) without relapses. Approval is based on positive phase 3 clinical trial res...
Akkodis' 2026 study reveals CTO confidence in scaling AI has fallen from 82% in 2024 to 48% in 2026, despite rapid AI adoption and increased investments. The main challenge is not technology but integrating AI into company systems, processes, and dec...
Akkodis' 2026 report reveals CTO confidence in scaling AI has fallen from 82% in 2024 to 48% despite increased AI adoption. The main challenge is no longer access to AI technology but integrating it into enterprise systems and workflows. Innovation h...
